Drugs / cysteine
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | CYSTEINE HYDROCHLORIDE | — | 1986-10-22 | fda.gov ↗ |
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT00253773 | Jan 2005 → Nov 2007 | disorder of defective peroxisome oxidative status | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Completed | No outcome recorded |
| — | NCT00253760 | Feb 2004 → Feb 2007 | diabetes mellitus, heart disorder | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Completed | No outcome recorded |
| — | NCT00004831 | Oct 1996 → Jul 1998 | erythropoietic protoporphyria | FDA Office of Orphan Products Development | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | cysteine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00253773 ↗ |
| Modality | Other / unclassified | “dietary amino acids; cysteine and methionine” NCT00253760 ↗ |
| Route | Oral | “receive cysteine hydrochloride orally twice daily” NCT00004831 ↗ |